These studies have demonstrated that APOBEC3B is a biomarker of poor prognosis and poor outcomes for estrogen receptor (ER)+  breast cancer, strongly indicating that genetic aberrations induced by APOBEC3B contribute to breast cancer progression [62–64]. Here, APOBEC3B is linked to breast cancer.